Genocea Biosciences (GNCA) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Genocea Provides Fourth Quarter 2021 Corporate Update
March 10, 2022 7:00 AM ESTInitial GEN-011 clinical trial data to be presented at AACR
Conference call today at 8:30 a.m. ET
CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today provided a business update for the fourth quarter ended December 31, 2021.
GEN-011 TiTANÂ trial update
Genocea is conducting the Phase I/2a TiTAN clinical trial for its lead program GEN-011, a neoantigen-targeted... More
